Gantenerumab Does Not Slow Clinical Decline in Early Alzheimer Disease
Two trials show lower amyloid plaque burden with gantenerumab versus placebo at 116 weeks
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.